In the clinical setting, previous studies have demonstrated that altered MLL5 transcript levels have prognostic implications in acute myeloid leukemia (AML)8 and acute promyelocytic leukemia (APL)9. The gene discussed is KMT2E; the disease is acute promyelocytic leukemia.